171 related articles for article (PubMed ID: 26189437)
21. Gender-dependent association of
Ioannou C; Ragia G; Balgkouranidou I; Xenidis N; Amarantidis K; Koukaki T; Biziota E; Kakolyris S; Manolopoulos VG
Pharmacogenomics; 2021 Jul; 22(11):669-680. PubMed ID: 34100299
[No Abstract] [Full Text] [Related]
22. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
Iacopetta B; Grieu F; Joseph D; Elsaleh H
Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832
[TBL] [Abstract][Full Text] [Related]
23. Identification of a novel single nucleotide polymorphism in the first tandem repeat sequence of the thymidylate synthase 2R allele.
Lincz LF; Scorgie FE; Garg MB; Ackland SP
Int J Cancer; 2007 May; 120(9):1930-4. PubMed ID: 17278107
[TBL] [Abstract][Full Text] [Related]
24. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Hamzic S; Kummer D; Froehlich TK; Joerger M; Aebi S; Palles C; Thomlinson I; Meulendijks D; Schellens JHM; García-González X; López-Fernández LA; Amstutz U; Largiadèr CR
Pharmacol Res; 2020 Feb; 152():104594. PubMed ID: 31838077
[TBL] [Abstract][Full Text] [Related]
25. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.
Kawakami K; Watanabe G
Cancer Res; 2003 Sep; 63(18):6004-7. PubMed ID: 14522928
[TBL] [Abstract][Full Text] [Related]
26. Distribution of the most common polymorphisms in TYMS gene in Slavic population of central Europe.
Pastorakova A; Chandogova D; Chandoga J; Luha J; Bohmer D; Malova J; Braxatorisova T; Juhosova M; Reznakova S; Petrovic R
Neoplasma; 2017; 64(6):962-970. PubMed ID: 28895423
[TBL] [Abstract][Full Text] [Related]
27. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
Rosmarin D; Palles C; Pagnamenta A; Kaur K; Pita G; Martin M; Domingo E; Jones A; Howarth K; Freeman-Mills L; Johnstone E; Wang H; Love S; Scudder C; Julier P; Fernández-Rozadilla C; Ruiz-Ponte C; Carracedo A; Castellvi-Bel S; Castells A; Gonzalez-Neira A; Taylor J; Kerr R; Kerr D; Tomlinson I
Gut; 2015 Jan; 64(1):111-20. PubMed ID: 24647007
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
[TBL] [Abstract][Full Text] [Related]
29. G>C SNP of thymidylate synthase with respect to colorectal cancer.
Gusella M; Padrini R
Pharmacogenomics; 2007 Aug; 8(8):985-96. PubMed ID: 17716232
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms of thymidylate synthase gene 5'- and 3'-untranslated region and risk of gastric cancer in Koreans.
Yim DJ; Kim OJ; An HJ; Kang H; Ahn DH; Hwang SG; Oh D; Kim NK
Anticancer Res; 2010 Jun; 30(6):2325-30. PubMed ID: 20651387
[TBL] [Abstract][Full Text] [Related]
31. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel.
Nief N; Le Morvan V; Robert J
Eur J Cancer; 2007 Mar; 43(5):955-62. PubMed ID: 17317154
[TBL] [Abstract][Full Text] [Related]
32. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
Ichikawa W; Takahashi T; Suto K; Sasaki Y; Hirayama R
Clin Cancer Res; 2006 Jul; 12(13):3928-34. PubMed ID: 16818689
[TBL] [Abstract][Full Text] [Related]
33. [Polymorphisms of thymidylate synthase gene and correlation of its protein expression to lymph node metastasis of esophageal squamous cell carcinoma].
Dong ZM; Cui YJ; Kuang G; Wang R; Yu FL; Zhang JH
Ai Zheng; 2005 Oct; 24(10):1225-9. PubMed ID: 16219137
[TBL] [Abstract][Full Text] [Related]
34. Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
Prall F; Ostwald C; Schiffmann L; Barten M
Oncol Rep; 2007 Jul; 18(1):203-9. PubMed ID: 17549369
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R
Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523
[TBL] [Abstract][Full Text] [Related]
36. Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS).
Kim SR; Ozawa S; Saito Y; Kurose K; Kaniwa N; Kamatani N; Hamaguchi T; Shirao K; Muto M; Ohtsu A; Yoshida T; Matsumura Y; Saijo N; Sawada J
Drug Metab Pharmacokinet; 2006 Dec; 21(6):509-16. PubMed ID: 17220568
[TBL] [Abstract][Full Text] [Related]
37. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity.
Kim SR; Park CH; Park S; Park JO; Lee J; Lee SY
Chemotherapy; 2010; 56(4):313-7. PubMed ID: 20714149
[TBL] [Abstract][Full Text] [Related]
39. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene.
Uchida K; Hayashi K; Kawakami K; Schneider S; Yochim JM; Kuramochi H; Takasaki K; Danenberg KD; Danenberg PV
Clin Cancer Res; 2004 Jan; 10(2):433-9. PubMed ID: 14760062
[TBL] [Abstract][Full Text] [Related]
40. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
